Preparing Clinical Outcome Assessments for APAC trials: What sponsors need to plan for

Disease affects us all, regardless of whether we are European, Asian, African, or North or South American. Clinical research, however, does indeed vary from region to region.  In 2026, the Asia-Pacific (APAC) region registers the most clinical trials of any World Health Organization region. Not only does APAC lead in the number of registered clinical trials, but it also offers sponsors 60 percent lower trial costs compared to western market rates, and patient enrollment two to five times faster than comparable US sites. Furthermore, the NMPA has accepted foreign clinical trial data under ICH guidelines since 2017. This combination of breadth, speed and cost is why so many global programs now build China and Japan into their trials from the outset rather than adding them later as a bridging study. As more sponsors incorporate APAC countries into global studies from the start, they also encounter new operational considerations. Clinical outcome assessments (COAs), in particular, require more planning than many teams anticipate. 

Many global trials use established COAs across multiple regions to maintain consistency in endpoint measurement and support regulatory submissions. However, clinical outcome assessments do not cross borders as easily as the rest of a study protocol. An instrument developed and validated in English reflects assumptions about language, culture, response options, and everyday experiences that do not automatically hold in Mandarin, Japanese, or other APAC languages. Differences in language, culture, and interpretation can affect how patients understand questions, use response scales, and report their experiences. Thus, beyond simply linguistic translation, using a Western COA in an APAC trial also requires culturally appropriate adaptation, evidence that the translated version measures concepts equivalently, and sufficient time for regulatory and operational readiness. Sponsors that postpone this work until after protocol finalization frequently discover that COA readiness has become a critical path, delaying site activation and increasing costs. Understanding what needs to happen, and when, is essential for keeping global APAC studies on schedule. 
 

What sponsors should plan for 

The majority of COA-related delays are avoidable, provided researchers recognize that preparing an instrument for use in APAC requires more than translating the text. To use a Western-developed COA in APAC trials, sponsors must: 

• Confirm whether a validated version already exists. Before commissioning a new translation, determine whether a validated, licensable version of the instrument is already available for your target country and population. In some cases, multiple translations of the same COA exist, while in others, an existing version may not meet the study's needs. Identifying what is already available can save both time and cost. 
   
• Plan for adaptation, not just translation. Translation is only one step in preparing a COA for use in another region. Depending on the instrument and study design, sponsors may also need cultural adaptation, cognitive interviewing with patients, and evidence that the translated version measures the same concepts as the original. Each activity has its own timeline and should be incorporated into study planning. To support these activities, Mapi Research Trust partners with ICON Language Services to provide translation, linguistic validation, and cultural adaptation for clinical outcome assessments. 
   
• Understand country-specific expectations. While international standards provide a foundation for COA translation and adaptation, regulators and ethics committees may have additional expectations for patient-facing materials and supporting documentation. Planning for these requirements early helps avoid delays during study startup and regulatory review. 
   
• Start COA planning before protocol lock. The most successful global studies begin COA planning alongside protocol development. Early planning provides time to confirm licensing, identify existing translations, address validation needs, and build realistic timelines before site activation becomes the critical path. 
   

Early planning protects both timelines and data quality 

APAC continues to offer sponsors significant advantages in speed, cost, and patient access. Realizing those advantages, however, requires the same level of planning for clinical outcome assessments as for any other critical study activity. 

By treating COA translation and cultural adaptation as strategic components of global trial design, sponsors can avoid unnecessary delays, preserve the integrity of endpoint data, and keep multinational studies on schedule.